QUANTA-CLOUD-TECHNOLOGY
Quanta Cloud Technology (QCT), a global data center solution provider, will showcase its cutting-edge High-performance Computing (HPC) and AI solutions with vertical applications at the ISC High Performance Conference 2022 , from May 29 to June 2 in Hamburg, Germany at Booth D412 . These unique solutions combine QCT’s advanced hardware infrastructures with software technologies to help build scalable, converged HPC and AI environments across many industries while shortening the time to implement projects so researchers can fully concentrate on their research.
QCT will showcase the following solutions and servers that drive faster time-to-value:
- QCT Platform on Demand (QPOD): QPOD is a workload-driven and purpose-built solution for academia, research institutes, or medical centers, fully integrated with hardware infrastructures, cluster deployment, monitoring and management tools to fulfill HPC and AI workloads. On top of the infrastructure, QCT has also worked with application ISVs to ensure the solution is pre-configured and pre-validated for HPC applications.
- High Performance Storage: Enabled by Intel® Optane™ persistent memory, Distributed Asynchronous Object Storage (DAOS) offers dramatic improvements to storage I/O to accelerate HPC, AI, analytics, and cloud projects. QCT’s advanced storage servers equipped with the DAOS open-source software-defined object store have also brought world-class IOPS and bandwidth as they have ranked on the IO500 and 10-Node Challenge during SC21.
- QuantaGrid D53X-1U: a 1U compute node server optimized by 3rd Gen Intel® Xeon® Scalable processors with built-in AI Accelerators and Intel® Optane™ persistent memory 200 series to propel DAOS and enable AI, HPC and virtualization workloads.
- QuantaGrid D53XQ-2U: a 2U server that benefits from DAOS fueled by Intel® Optane™ persistent memory on the Intel Xeon Scalable platform and equipped with acceleration card expansion slots to power AI, analytics, bioscience, HPC, and even cloud computing workloads.
For more information on QCT’s high-performance storage product line, join QCT’s speaking session titled “Innovative High-performance Storage for AI/HPC in the Exascale Era” at the HPC Solutions Forum (Hall H, Booth J901) on May 31 at 2:00 pm. Our Technical Manager and Solution Architect, Grover Hwang, will give a deep dive on using DAOS to achieve less I/O wait and lower latency when running real-world AI/HPC applications.
“QCT is excited to bring our latest HPC solutions built for compute and graphic-intensive workloads to ISC 2022,” said QCT President Mike Yang. “As an infrastructure builder, QCT leverages our robust R&D capabilities and strong software ecosystem support to tune our solutions all the way from hardware to the software stack, accelerating digital transformation in fields across weather forecasting, NGS, molecular dynamics and more.”
Visit QCT Booth D412 at ISC22 and http://www.qct.io to learn more.
About QCT
QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. http://www.qct.io
Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005020/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release
SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom